T.P. MAKAROVA¹, A.B. SHIMANOVA², YU.S. MELNIKOVA¹, A.P. SOLONENKO², G.G. MALUDZE², S.S. SELIVANOVA³

 ¹Kazan State Medical University, Kazan

²Children’s Republic Clinical Hospital, Kazan

³Almetyevsk Regional Children’s Hospital with a perinatal center, Almetyevsk

Contact details:

Makarova T.P. — MD, Professor, Department of Hospital Pediatrics

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-903-313-82-98, e-mail: makarova-kgmu@mail.ru

 Dyslipidemia in chronic kidney disease (CKD) is an important factor influencing the progression of renal pathology and the development of cardiovascular complications. The article discusses the pathogenetic mechanisms of dyslipidemia in children and adults with CKD, as well as the role of apolipoproteins in the regulation of lipid metabolism and renal tissue damage. It is shown that the dyslipidemia spectrum in renal pathology differs from that in the general population. Changes in lipid metabolism occur already in the early stages of CKD and worsen as renal damage progresses. The importance of using apolipoproteins in diagnosing hyperlipidemia is emphasized, which contributes to more accurately determining the defect in lipoprotein metabolism and selecting adequate medication or dietary therapy. Their study opens up prospects for more accurate diagnostics, prognostic stratification, and development of personalized treatment strategies.

Key words: dyslipidemia, chronic kidney disease, apolipoproteins, hypercholesterolemia, nephrotic syndrome.

REFERENCES

1. Lebedeva E.N., Vyalkova A.A., Afonina S.N., Chesnokova S.A. Dyslipidemia as a pathogenetic factor in the progression of chronic kidney disease. Nefrologiya, 2019, no. 23, pp. 56–64 (in Russ.).
2. Kontsevaya A.V., Balanova Yu.A., Imayeva A.E., Khudyakov M.B., Karpov O.I., Drapkina O.M. Economic damage from hypercholesterolemia at the population level in the Russian Federation. Ratsional′naya farmakoterapiya v kardiologii, 2018, vol. 14, no. 3, p. 393 (in Russ.).
3. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H. et al. ESC Scientific Document Group. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J, 2016, vol. 37 (39), pp. 2999–3058. DOI: 10.1093/eurheartj/ehw272
4. Mamedov M.N., Karimov A.K. Secondary hyperlipidemia: features of manifestation in various somatic diseases. Profilakticheskaya meditsina, 2021, vol. 24, no. 3, p. 105110 (in Russ.).
5. Kulakova E.N., Bayko S.V. Dyslipidemia in children and adolescents with CKD C1-C5, on dialysis and after transplantation: a descriptive review of clinical studies and recommendations for management tactics. Nefrologiya i dializ, 2025, vol. 27, no. 1, pp. 38–58 (in Russ.).
6. Sadykova D.I., Galimova L.F., Slastnikova E.S. Features of the diagnosis of familial hypercholesterolemia in children. Pediatriya, 2020, vol. 17, no. 2, p. 124 (in Russ.).
7. Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines 2022. Kardiovaskulyarnaya terapiya i profilaktika, 2022, vol. 21, no. 4, p. 3235 (in Russ.).
8. Rudenko T.E., Kutyrina I.M., Shvetsov M.Yu. Lipid metabolism in chronic kidney disease. Klinicheskaya nefrologiya, 2012, no. 2, pp. 14–21 (in Russ.).
9. Bhargava P., Schnellmann R.G. Mitochondrial energetics in the kidney. Nat. Rev. Nephrol, 2017, no. 13, pp. 629–646.
10. Mack S., Coassin S., Vaucher J., Kronenberg F., Lamina S. ApoA-IV-GWAS consortium. Evaluating the causal relation of ApoA-IV with disease-related traits — A bidirectional two-sample mendelian randomization study. Sci. Rep, 2017, vol. 7 (1), p. 8734. DOI: 10.1038/s41598-017-07213-9
11. Bulbul M.C., Dagel T., Afsar B., Ulusu N.N., Kuwabara M., Covic A., Kanbay M. Disorders of lipid metabolism in chronic kidney disease. Blood Purif, 2018, vol. 46 (2), pp. 144–152. DOI: 10.1159/000488816
12. Won H., Bae J.H., Lim H., Kang M., Kim M., Lee S. 2024 KSoLA consensus on secondary dyslipidemia. Korean J. Int. Med, 2024, vol. 39 (5), pp. 717–730.
13. Suh S.H., Kim S.W. Dyslipidemia in patients with chronic kidney disease: An updated overview. Diabetes Metabol. J, 2023, vol. 47, pp. 612–629.
14. Lamprea-Montealegre J.A., Staplin N., Herrington W.G., Haynes R., Emberson J., Baigent C., de Boer I.H., on behalf of the SHARP Collaborative Group. Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin. J. Am. Soc. Nephrol, 2020, vol. 15, pp. 47–60.
15. Ooi E.M.M., Chan D.T., Watts G.F., Chan D.C., Ng T.W.K., Dogra G.K. et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J. Lipid Res, 2011, vol. 52, pp. 794–800.
16. Chan D.T., Dogra G.K., Irish A.B., Ooi E.M., Barrett P.H., Chan D.C., Watts G.F. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J. Lipid Res, 2009, vol. 50, pp. 2524–2531.
17. Saland J.M., Pierce C.B., Mitsnefes M.M., Flynn J.T., Goebel J., Kupferman J.C. et al. CKiD Investigators. Dyslipidemia in children with chronic kidney disease. Kidney Int, 2010, vol. 78 (11), pp. 1154–1163. DOI: 10.1038/ki.2010.311
18. Baek H.S., Kim S.H., Kang H.G., Choi H.J., Cheong H.I., Ha I.S. et al. Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (Korean cohort study for Outcomes in patients with Pediatric CKD). Pediatr. Nephrol, 2020, vol. 35 (8), pp. 1455–1461. DOI: 10.1007/s00467-020-04545-z